When a pharmaceutical QA team asks whether a piece of software is validated, they aren't asking whether it works well. They're asking a regulatory question: can the use of this software in a GxP process be defended in an FDA or EMA inspection?
The answer decides whether the records that software produces can be trusted. In a regulated environment, an untrustworthy record isn't just a paperwork issue. It can call into question every decision that relied on it.
What IQ, OQ, and PQ Mean
Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) are the three classic stages of demonstrating that a system is fit for its intended use:
- IQ confirms the system is installed correctly and configured as specified.
- OQ confirms it performs as intended across its defined operating range.
- PQ confirms it performs consistently under real operating conditions, with real users and real data.
They're a familiar structure, not a fixed legal formula. What regulators actually require is evidence that a computerized system does what it's supposed to do, reliably, for its intended use. IQ, OQ, and PQ are the most common way to organize that evidence.
Validation Is Becoming More Risk-Based
The way that evidence is gathered is shifting, on both sides of the Atlantic.
In the US, FDA finalized its Computer Software Assurance (CSA) guidance in September 2025 and updated it in 2026 to align with the new device Quality Management System Regulation. CSA moves away from exhaustive scripted testing of every function toward assurance activities matched to risk: more rigor where a failure could affect product quality or patient safety, less where it can't. Formally, CSA applies to software used in medical device production and quality systems, but it reflects a direction that pharma validation practice, including ISPE's GAMP 5 framework, has also been moving toward. We looked at a related shift in ISPE's Good Practice Guide on digital validation.
In the EU, the draft revision of Annex 11 on computerized systems, published for consultation in July 2025, treats validation as a lifecycle obligation. It expands expectations on risk management, supplier oversight, audit trails, and scheduled periodic review. The draft hasn't been finalized yet, and the 2011 version still applies, but it's a clear signal of where inspections are heading.
The common thread: validation isn't a one-time certificate filed at go-live. It's an ongoing, risk-based demonstration that a system stays fit for its intended use as it's updated, reconfigured, and used in new ways.
Why This Applies to Label Comparison Tools
Using unvalidated software in a GxP process creates a specific risk, even if the software works perfectly. If it produces or supports a record that feeds into a batch release or labeling decision, that record may not be defensible under 21 CFR Part 11 or EU Annex 11.
That applies directly to proofreading and document comparison tools. When a tool verifies that a label revision matches the approved master, it's supporting a release decision. Under a risk-based approach, that's exactly the kind of function that warrants rigorous assurance. A tool that's fine for comparing general documents may not be validated for pharmaceutical quality use. (We cover common Part 11 misreadings in 21 CFR Part 11: The Compliance Assumptions Pharma Teams Make.)
It also matters how the tool works. A deterministic comparison, where the same input always produces the same, traceable result, is far easier to validate than a system whose output can vary between runs. That distinction is becoming more important as AI features appear in quality tools, as we discuss in How Pharma Teams Stay Compliant in an AI World.
What to Ask a Vendor About Validation
For comparison and proofreading software used in labeling, ask:
- What validation documentation do you provide: test plan, risk assessment, executed test cases?
- Who performs the IQ, and when?
- Does one validation cover all comparison types, or does each module need its own?
- How are new software releases handled, and what documentation comes with each one?
- How does your approach support a risk-based validation strategy rather than just scripted testing?
Our Buyer's Guide to Artwork Verification Software covers these questions in more detail.
Content Compare includes a validation package with every deployment: test plan, risk assessment, and executed test cases, with Installation Qualification completed as part of onboarding and all four modules covered under a single validation. See what onboarding looks like, or book a demo.
